Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q1 2015 · 10-Q
Revenue—
Net Income-$3.07M-$3.07MN/M vs Q1 2014 EPS Diluted-$0.09-$0.09N/M vs Q1 2014 Operating Income-$7,865,514N/M Operating Cash Flow-$5,813,050N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Mar 31, 2015 · filed May 8, 2015 · 38 d after period end